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Abstract
Objective: Development of liposomal mucoadhesive drug delivery system, which is able to improve the
bioavailability of poorly absorbed oral drugs by prolonging their gastric and intestinal residence time,
through facilitating the intimate contact of the delivery system with the absorption membrane. Materials
and methods: Liposomes containing model drug atenolol were prepared by the modified ethanol injection
method. Liposomes containing atenolol were coated by different mucoadhesive polymers, for example,
chitosan, Carbopol 974P, Eudragit L100, and Eudragit S100, to optimize the choice of coating material. The
delivery systems were tested for their in vitro mucoadhesiveness. Results: Liposomes prepared by the ethanol
injection method were of satisfactory size (around 100 nm, before coating). Through the coating of lipo-
somes in the presence of unentrapped material, the entrapment efficiency for drug was increased. In vitro
mucoadhesive test confirmed the mucoadhesive properties of the coated layer for all tested polymers;
however, Eudragit S100-coated liposomes were superior to other coating materials. Discussion: Eudragit
coating appeared to be an optimal polymer choice. These preliminary data indicate that polymer-coated
mucoadhesive liposomes are able to carry sufficient amount of drug and to remain attached to the intestinal
mucosa for a sufficient period of time to enable prolonged absorption of entrapped drug. Conclusion:
While keeping in mind that the in vivo conditions may vary with the in vitro ones, we may recommend the
system described in our work for possible oral delivery of peptides and phytochemicals.
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Introduction
With the rapid progress in pharmaceutical technology,
delivery of therapeutic proteins/peptides has received a
considerable amount of attention over the past 10 years
for potential clinical applications1,2. The oral route
remains to be the most convenient and comfortable way
of drug administration, including peptide delivery.
However, peptide drugs are readily degraded under
the low pH of the gastric medium and by various pro-
teolytic enzymes in the gastrointestinal (GI) tract3. To
improve the oral absorption efficiencies, multifunctional
polymers exhibiting mucoadhesive, pH-dependent,
permeation-enhancing, enzyme inhibitory properties
have been used4,5.
One of the most promising strategies in developing
mucoadhesive particulate systems is surface modification,
or coating, of the drug carrier particles with mucoadhe-
sive polymers5,6. Liposomes were proposed as suitable
drug delivery systems for various types of drug mole-
cules, including proteins and peptides7. Liposomes possess
the advantages that they are composed of physiological
materials, for example, phospholipid, but are liable to be
destructed by the pH, bile salts, and pancreatic lipase in
the GI tract. Apart from these major barriers, fragile
nature and short in vitro half-lives of these bioactives
preclude many options to formulate an oral dosage
form. To minimize the destructive influences, the forma-
tion of a polymeric membrane around the liposome has
been proposed8,9.
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Mucoadhesive dosage forms have received substantial
attention as novel drug delivery systems able to improve
the bioavailability of drugs by prolonging their residence
time and controlling the drug release characteristics.
Mucoadhesive nanoparticulate systems such as polymer-
coated liposomes were found to be useful carriers for
improved oral delivery because of their prolonged reten-
tion in the GI tract and excellent penetration into the
mucus layer5. The mucoadhesive liposomes can be pre-
pared by coating drug carrier surface by various mucoad-
hesive polymers such as chitosan10–13, Carbopol9,14,15,
and Eudragit16. Chitosan {poly [b-(1–4)-2-amino-2-deoxy-
D-glucopyranose]} is the second abundant natural-origin
polysaccharide next to cellulose and, over the past two
decades, has been used for various biomedical and drug
delivery applications because of its low toxicity, good bio-
compatibility, and antimicrobial and mucoadhesive
properties. Its mucoadhesive properties are due to the
molecular attractive forces formed by the electrostatic
interaction between positively charged chitosan and neg-
atively charged mucosal surfaces17,18. Carbopol polymers
are polymers of acrylic acid cross-linked with polyalkenyl
ethers or divinyl glycol and they are also finding numer-
ous applications in oral mucoadhesive drug delivery
because of their ability to interact with the mucus
glycoprotein and to remain localized to a specific
site14,15,19. Polymethacrylates for pharmaceutical pur-
poses became known under the trademark Eudragit.
Eudragit L100 is an anionic polymer synthesized from
methacrylic acid and methacrylic acid methyl ester and
has a pH-dependent solubility. It is slowly soluble in
intestinal fluid that is mildly acidic to neutral. Eudragit
L100, as an enteric coating material, is soluble above pH
6.0 medium, which can protect the protein drugs from the
acidic environment in the stomach20. Eudragit S100 is an
anionic polymer synthesized from methacrylic acid and
methacrylic acid methyl ester and has a pH-dependent
solubility. It is slowly soluble in the region of GI tract
where juices are neutral to weakly alkaline21.
By the right combination of liposomal and polymer
characteristics, it is possible to develop delivery system
with specific, prolonged, and controlled release22.
The objective of this work was to optimize the
mucoadhesive liposomal delivery system for oral admin-
istration of peptides and possibly phytochemicals by the
optimization of coating mucoadhesive material. The
vesicle size before and after coating, entrapment effi-
ciencies for model drug atenolol, and the mucoadhesive
strength of the delivery systems based on chitosan, Car-
bopol, and Eudragit coatings were used as parameters in
evaluating the optimal formulation.
Materials and methods
Materials
Eudragit S100 and Eudragit L100 (Rohm GmbH & Co.
KG, Darmstad, Germany) were kindly provided by LS
Pharmazeutishe Technologie, Pharmazeutishes Insti-
tut, Freiburg University, Germany. Carbopol 974P
(BF Goodrich, Cleveland, OH, USA) and atenolol
(Atenolol IP, IPCA Laboratories, Mumbai, India) were
generous gifts of Quest Pharmaceuticals, Birganj,
Nepal. Chitosan (LMW) was purchased from Sigma
(Tokyo, Japan). Lecithin was from Siegfried AG (Zofingen,
Germany). Lipoid S100 and Lipoid S75 were generous
gifts from Lipoid GmbH (Ludwigshafen, Germany). The
other chemical reagents and solvents used were of ana-
lytical grade. Pig intestinal membrane from freshly
slaughtered animal was purchased from the local
slaughterhouse.
High-performance liquid chromatography analysis of 
atenolol
The analyses were performed on a Shimadzu chro-
matographic system equipped with high-performance
liquid chromatography (HPLC) Shimadzu pump
LC-20AD, a Shimadzu SPD-20A UV spectrophotome-
ter. (Tokyo, Japan) The column RP18 Fluofix 3NW415
(4.60×150 mm) was joined with precolumn. The
mobile phase consisted of a mixture of acetonitrile/
methanol/0.01 M phosphate buffer with pH adjusted to
6.0 with 0.1 M NaOH, containing 0.1% sodium dodecyl
sulfate (34:33:33, v/v/v), pumped at a flow rate of
1.0 mL/min23. The eluting compounds were monitored
at UV 258 nm and temperature of the column was
maintained at 30°C during the chromatographic sepa-
ration. The retention time of the atenolol was deter-
mined to be 5.3 minutes.
Preparation of liposomes
Liposomes were prepared by the modified ethanol injec-
tion method24. Three types of lipids, namely, Lipoid
S100, Lipoid S75, and lecithin, were used in the prepara-
tions (Table 1). Lipid was dissolved in absolute ethanol
(25–100 mg/mL) mixed with either ethanol or the ethan-
olic solution of atenolol (10–30 mg/mL) and 1.5 mL of
such a mixed solution rapidly injected into 20 mL of
magnetically stirred phosphate buffer saline (PBS; pH
7.4; Table 1). Stirring was continued for 1 hour and the
liposomal suspension was left overnight in refrigerator
to stabilize before characterization. The final ethanol
concentration (7.5%) and the rate of stirring were kept
constant for all preparations.
Coating of liposomes
Chitosan coating
For the preparation of chitosan-coated liposomes, 0.1%
and 0.6% (w/v) chitosan solutions were prepared in 0.1%
(v/v) glacial acetic acid25. A volume of 2.0 mL of chitosan
solution was added drop-wise to the 2.0 mL of liposomes
under magnetic stirring at room temperature for 1 hour,
followed by incubation in refrigerator overnight. The
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Carbopol coating
For the preparation of Carbopol-coated liposomes, 0.1%
and 0.6% (w/v) Carbomer 974P was dissolved in PBS 7.4.
A volume of 2.0 mL of Carbopol solution was added
drop-wise to the 2.0 mL of liposomes under magnetic
stirring at room temperature for 1 hour, followed by
incubation in refrigerator overnight. The rate of stirring
was kept constant for all preparations by this method.
Eudragit coating
For the Eudragit coating two types of Eudragit, namely,
Eudragit S100 and Eudragit L100 were used. The method
applied was the modification of the method used for chito-
san coating. Eudragits were dissolved in acetone containing
3.0% of water and drop-wise added to liposomes and left
overnight in refrigerator to stabilize before characterization.
Particle size determination
Hydrodynamic diameter S (dh) of liposomes and polymer-
coated liposomes was measured by dynamic light scat-
tering (DLS) with a vertically polarized He–Ne laser
beam at a wavelength of 633 nm (Zetasizer 3000 HS,
Malvern Instruments, Malvern, UK). The scattering
angle was fixed at 90° and the temperature was maintained
at 25°C. The samples were filtered through 1.20-μm mem-
brane before measurements (Chromafil® Macherey-
Nagel, Detlef Lambrecht, Germany). Analyses were
made using the CONTIN algorithm.
Zeta potential determination
The formation of chitosan layer on liposomal surface was
confirmed by measuring the zeta potential on vesicle sur-
face. Zeta potential of the uncoated and chitosan-coated
(0.6%, w/v) vesicles was determined using a Zetasizer
Nano Z (Malvern Instruments). Three measurements of
the two samples for each type of vesicles were analyzed.
Entrapment efficiency determination
Dialysis was applied to separate unentrapped atenolol
from liposomes or polymer-coated liposomes10. The
liposomal samples (4.0 mL) and the polymer-coated
liposomal samples (3.0 mL) were placed in tubing and
extensively dialyzed against the PBS 7.4 for 24 hours. The
dialysis was continued for 48 hours in total. The volume
of buffer was adjusted so that the concentration of drug
in the buffer was kept below the solubility of drug. The
drug concentration (unentrapped) was determined
spectrophotometrically.
After removal of unentrapped material, liposomes
were destroyed using methanol and the actual content of
drug in the sample was determined by the HPLC method.
For this, 500 μL of liposomal suspension was mixed
thoroughly with 2.0 mL of methanol and the solution was
filtered through the hexamethylenediamine, nylon-66
membrane filter of pore size 0.20 μm. For the coated lipo-
somes, the destruction was done using the methanol and


































ATLCh01 6.6 20 0.1
ATLCh06 6.6 20 0.6
ATLCa01 6.6 20 0.1
ATLCa06 6.6 20 0.6
ATLEuL01 6.6 20 0.1
ATLEuL06 6.6 20 0.6
ATLEuS01 6.6 20 0.1
ATLEuS06 6.6 20 0–6
EL, empty liposomes; ATL, liposomes containing atenolol, uncoated; ATLCh, ATL coated with chitosan; ATLCa, ATL coated with Carbopol 940;
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chloroform in the ratio of 2:1. A volume of 20 μL of clear
solution was injected and the concentration of drug was
calculated directly by measuring the peak area through
the standard calibration curve of atenolol.
In vitro wash-off test for mucoadhesive testing
The mucoadhesive property of the polymer-coated lipo-
somes was evaluated by an in vitro adhesion test. The
method used was the modified in vitro wash-off test26.
The mucoadhesion of the polymer-coated liposomes was
compared with that of a nonmucoadhesive material,
uncoated liposomes containing atenolol. Freshly excised
pieces of pig intestinal mucosa (2 × 2 cm) were tightened
onto glass slides (3 × 1 inches) with thread. A volume of
500 μL of the liposomes, 0.6% (w/v) chitosan-coated lipo-
somes, 0.6% (w/v) Carbopol-coated liposomes, 0.6% (w/
v) Eudragit S100, and 0.6% (w/v) Eudragit L100-coated
liposomes were spread onto each wet-rinsed tissue spec-
imen and immediately incubated at 37°C. The tissue
specimens were taken out at 1 and 3 hours. The samples
were washed with 10.0 mL of PBS at each time interval.
The results were evaluated based on the t-test compari-
son between uncoated and polymer-coated liposomes.
Determination of mucoadhesive strength
From the 10.0 mL of the eluted buffer containing nonad-
hered drug, 500 μL aliquots were taken and liposomal
lipids were dissolved by methanol. From the clear solu-
tion, a volume of 20 μL was injected and the peak area
was measured by HPLC.
The concentration of atenolol eluted in the buffer
(PBS 7.4) was measured and the remaining drug was
assumed to be present in liposomes adhered to the
intestinal mucosa. Hence, the percentage of mucoadhe-
sive strength can be calculated by Equation (1)
Results and discussion
Atenolol determination
HPLC analysis confirmed single peak of atenolol (Figure 1)
with the linearity of the standard curve obtained in the
range of 10–100 μg/mL resulting in the correlation coef-
ficient of 0.9998.
Particle size analysis
Comparison of particle size of empty liposomes, liposomes 
containing drug, and polymer-coated liposomes containing 
drug
Particle size of vesicles affects the biological properties
of delivery system. The mucoadhesiveness of the coated
liposomes was reported to be dependent on the particle
size, and submicron-sized chitosan-coated liposomes
were found to be more effective than the chitosan-
coated liposomes of bigger size. The mucoadhesive
property of smaller-size chitosan-coated liposomes is
the result of chitosan coating attributing to the longer
retention in the intestinal tract27.
As the first step in developing mucoadhesive lipo-
somes of desired particle size distribution, we examined
the effect of the purity of phospholipids used for liposo-
mal preparation. The liposomal size and polydispersity
indexes, as determined by photon correlation spectros-
copy, revealed rather large particles with broad size dis-
tribution in the case of liposomes made of lecithin even
before the actual coating procedure (Table 2); thereof,
we decided to use further only pure phosphatidylcholine
such as Lipoid S100. Moreover, polydispersity indexes
for liposomes containing atenolol prepared from Lipoid
S100 revealed more uniform size distributions with
lower polydispersity index. During the size distribution
measurements by the DLS method, it was observed that
the mean diameter of the whole population was affected
by a very small population of relatively larger vesicles
which contributed to increased polydispersity index.
Therefore, we used membrane filter with pore size of
1.20 μm to filter liposomal samples before measurement
Mucoadhesion 
Amount of drug remaining in mucosa
Amount 
(%) =







Figure 1. Typical HPLC chromatogram of standard atenolol. Chro-
matographic conditions: column: Fluofix (4.6 × 150 mm); column
temperature: 30°C; mobile phase: acetonitrile : methanol: 0.01 M
phosphate buffer pH 6.0 (34:33:33); detector UV at 258 nm; flow rate:
1 mL/min; chart speed: 5 mm/min; and retention time: 5.3 minutes.





Table 2. Particle size analysis of liposomes prepared by the ethanol











EL1 Lecithin — 241.3 ± 17.6 0.890
EL2 Lipoid S75 — 184.2 ± 20.3 0.699
EL3 Lipoid S100 — 97.7 ± 1.51 0.365
ATL1 Lecithin 6.66 281.6 ± 5.9 0.760
ATL2 Lipoid S75 6.66 167.2 ± 14.0 0.672
ATL3 Lipoid S100 6.66 89.0 ± 3.5 0.223
The amount of lipid used in all formulations was 20 mg. The values
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to eliminate this small population of larger vesicles or
agglomerates. After this intervention, the mean size of
liposomes did not change significantly, but the polydis-
persity index was reduced. During the filtration, less
than 5% of original total amount of lipid was lost (data
not shown) as determined by the phospholipid assay.
The ethanol injection method is one of the simplest
liposomal preparation methods. Liposomes prepared by
this method are expected to be of 100 nm in diameter. In
our results, liposomes with model drug have particle size
below 100 nm (Figure 2). The mean diameter of empty
liposomes was 97.7 nm, whereas liposomes containing
atenolol were 89.0 nm in size. Similar results were
reported by Filipovic-Grcic et al.10 The particle size of
polymer-coated liposomes in each formulation has
increased with the increasing concentration of polymer
solution used in the coating, suggesting the formation of
coating layer on the surface of the liposomes and an
increase in thickness of the coating layer with an
increase in the concentration of polymer solution as
observed by Filipovic-Grcic et al.10, Wu et al.28, and
Shende and Gaud29. By the increase in the concentration
of polymer used for coating, the increase of the mean
particle size was observed, however, the reason for the
increase in size might not be only the consequence of
the formation of coating layer on liposomal surface, but
possible agglomerates of two or more vesicles stacked
together, which cannot be distinguished from this mea-
surement method.
In addition, the zeta potential measurements of
uncoated and chitosan-coated (0.6%, w/v) vesicles con-
firmed the presence of polymer layer on liposomal sur-
face. The uncoated liposomes had zeta potential of –20 ±
3 mV, whereas chitosan-coated liposomes had zeta
potential of 27 ± 6 mV. The increase in zeta potential
values for chitosan-coated liposomes is in agreement
with Takeuchi and yamamoto.5
Entrapment efficiency for atenolol in uncoated and 
polymer-coated liposomes
The physicochemical properties of drug, especially its
solubility and partition coefficient, can be important
determinants for the extent of its liposomal incorpora-
tion. The degree or efficiency of drug entrapment in lipo-
somes, assessed as entrapment yield, depends on the
number of factors, including drug’s characteristics, lipo-
somal size, and liposomal composition24. The entrap-
ment efficiency for atenolol was calculated by HPLC
external standard method (Table 3, Figure 1). The
amount and the type of lipid were kept constant. The
efficiencies were found to vary and to be rather low. It is
probably the consequence of the hydrophilicity of drug
(log P = 0.16) and smaller liposomal size.
Figure 2. Particle size distribution of coated liposomes. The lipid used in all preparations was Lipoid S100. The values denote the mean ± SD of











































































Table 3. Entrapment efficiency for polymer-coated liposomes
containing atenolol.






— — 21.62 ± 0.92
Chitosan 0.1 24.68 ± 3.51
Chitosan 0.6 25.77 ± 0.29
Carbopol 0.1 22.19 ± 5.69
Carbopol 0.6 22.22 ± 0.33
Eudragit L100 0.1 26.09 ± 1.32
Eudragit L100 0.6 32.93 ± 0.06
Eudragit S100 0.1 31.53 ± 2.21
Eudragit S100 0.6 43.57 ± 0.51
Liposomes were prepared by the modified ethanol injection method
and coated in the presence of unentrapped material. The values
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The entrapment efficiency for atenolol was remark-
ably increased after coating in the presence of unen-
trapped atenolol, particularly in the case of Eudragit
coating (Table 3), suggesting that mucoadhesive coating
may have application for peptide and protein drugs
delivery10.
The entrapment efficiency was found to be higher in
all cases of polymer-coating of liposomes, but remark-
able results were obtained in the case of Eudragit L100-
and Eudragit S100-coated liposomes. The 0.6% (w/v)
Eudragit S100 increases the entrapment efficiency by
110%, whereas 0.6% (w/v) Eudragit L100 increases it
about 55%. Both Eudragit S100 and Eudragit L100 are
the anionic polymers of methacrylic acid with known
superiority in the intestinal drug delivery systems.
These polymers would be the suitable carrier for the
possible oral peptide or phytochemical drug delivery
systems20,21.
Based on our preliminary results, we suggest that by
the right choice of polymer used in coating, and depend-
ing on the characteristics of the drug to be entrapped in
liposomes, polymer-coated liposomes may encapsulate
sufficient amount of drug, and be a promising tool in
oral delivery of various molecules.
In vitro mucoadhesion testing of polymer-coated 
liposomes
The in vitro test of mucoadhesion was performed by the
modified wash-off method on pork intestine. The per-
centage of mucoadhesive strengths was calculated by
Equation (1) and the results demonstrated that the poly-
mer-coated liposomes have higher strength compared
with the nonmucoadhesive material (P < 0.05). After 3
hours of incubation, more than 68% of the originally
entrapped atenolol was retained on the intestinal
mucosa in the case of Eudragit S100-coated liposomes
containing atenolol (Figure 3). Both Eudragit L100- and
Eudragit S100-coated liposomes were found to possess
stronger mucoadhesive properties compared with chito-
san-coated and particularly Carbopol-coated liposomes.
The preliminary results presented in Figure 3 confirm
the possibility of using mucoadhesive polymer-coated
liposomes as a promising tool in oral delivery of various
molecules. One should keep in mind that in vivo situa-
tion may not directly follow the in vitro findings, because
in vivo conditions include the GI motility and peristaltic
movements which, in our experimental conditions, were
not present. However, the adhesive strength of 68%
observed in the present experiment might contribute to
significant mucoadhesion in in vivo conditions. When
deciding on the choice of coating material, several
parameters contribute to the decision. Based on the drug
entrapment efficiency and mucoadhesive strength, it
appears that Eudragit-coated liposomes possess supe-
rior properties to chitosan- and Carbopol-coated lipo-
somes. The decision will be effected by the short and
long stability of liposomal systems and the possibility for
scale up of the manufacturing process.
Conclusion
In an attempt to develop oral liposomal delivery system,
we used polymer-coating as means of improving liposo-
mal properties. As our target was the delivery system for
possible oral peptide and phytochemicals delivery, we
used atenolol as a model molecule. As a prerequisite for
successful delivery is the system’s mucoadhesiveness,
liposomes were coated with various polymers, namely,
Figure 3. Mucoadhesiveness of polymer-coated liposomes. Liposomes containing atenolol were prepared by the modified ethanol injection
method and coated by various polymers by procedures explained earlier. The mucoadhesiveness was tested by the modified wash-off method.
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chitosan, Carbopol, and Eudragit L100 and Eudragit
S100. The coating resulted in the increase in the original
entrapment efficiency, as the coating was performed in
the presence of unentrapped drug. Among tested poly-
mers, coating with Eudragit S100 resulted in the highest
entrapment and mucoadhesiveness. The consequence
of coating was the increase in original liposomal size.
The preliminary in vitro test of mucoadhesive properties
of polymer-coated liposomes showed promising results,
indicating that polymer-coated liposomes developed in
this study may have a promising future in oral delivery of
various molecules.
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